FLT3 mutations in a 10 year consecutive series of 177 childhood acute leukemias and their impact on global gene expression patterns

Genes Chromosomes and Cancer

Volumn 47, Issue 1, 2008, Pages 64-70

  Andersson, Anna ^a   Paulsson, Kajsa ^a,b   Lilljebjörn, Henrik ^a   Lassen, Carin ^a   Strömbeck, Bodil ^a   Heldrup, Jesper ^a   Behrendtz, Mikael ^c   Johansson, Bertil ^a   Fioretos, Thoas ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE;

ACUTE LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ANALYTIC METHOD; ARTICLE; B LYMPHOCYTE; CANCER DIAGNOSIS; CELL LINEAGE; CHILD; CHROMOSOME REARRANGEMENT; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; GENE DUPLICATION; GENE EXPRESSION; GENE MUTATION; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MYELOID LEUKEMIA; NEWBORN; POINT MUTATION; PRIORITY JOURNAL; SWEDEN; T LYMPHOCYTE;

ADOLESCENT; AGE FACTORS; CHILD; CHILD, PRESCHOOL; FEMALE; FMS-LIKE TYROSINE KINASE 3; GENE EXPRESSION REGULATION, LEUKEMIC; GENE FREQUENCY; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOID, ACUTE; MALE; MUTATION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA;

EID: 36549062926     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20508     Document Type: Article

References (50)

1. Abu-Duhier FM, Goodeve AC, Wilson GA, Care RS, Peake IR, Reilly JT. 2001. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 113:983-988.
2. Andersson A, Johansson B, Lassen C, Mitelman F, Billström R, Fioretos T. 2004. Clinical impact of internal tandem duplications and activating point mutations in FLT3 in acute myeloid leukemia in elderly patients. Eur J Haematol 72:307-313.
3. Andersson A, Edén P, Lindgren D, Nilsson J, Lassen C, Heldrup J, Fontes M, Borg Å, Mitelman F, Johansson B, Höglund M, Fioretos T. 2005a. Gene expression profiling of leukemic cell lines reveals conserved molecular signatures among subtypes with specific genetic aberrations. Leukemia 19:1042-1050.
4. Andersson A, Olofsson T, Lindgren D, Nilsson B, Ritz C, Edén P, Lassen C, Råde J, Fontes M, Mörse H, Heldrup J, Behrendtz M, Mitelman F, Höglund M, Johansson B, Fioretos T. 2005b. Molecular signatures in childhood acute leukemia and their correlations to expression patterns in normal hematopoietic subpopulations. Proc Natl Acad Sci USA 102:19069-19074.
5. Armstrong SA, Staunton JE, Silverman LB, Pieters R, den Boer ML, Minden MD, Sallan SE, Lander ES, Golub TR, Korsmeyer SJ. 2002. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 30:41-47.
6. Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, Den Boer ML, Pieters R, Kersey JH, Sallan SE, Fletcher JA, Golub TR, Griffin JD, Korsmeyer SJ. 2003. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 3:173-183.
7. Armstrong SA, Mabon ME, Silverman LB, Li A, Gribben JG, Fox EA, Sallan SE, Korsmeyer SJ. 2004. FLT3 mutations in childhood acute lymphoblastic leukemia. Blood 103:3544-3546.
8. Brown P, Levis M, Shurtleff S, Campana D, Downing J, Small D. 2005. FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression. Blood 105:812-820.
9. Chen W, Jones D, Medeiros LJ, Luthra R, Lin P. 2005. Acute myeloid leukaemia with FLT3 gene mutations of both internal tandem duplication and point mutation type. Br J Haematol 130:726-728.
10. Fröhling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K, Döhner H, Döhner K. 2002. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: A study of the AML Study Group Ulm. Blood 100:4372-4380.
11. Hayakawa F, Towatari M, Kiyoi H, Tanimoto M, Kitamura T, Saito H, Naoe T. 2000. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 19:624-631.
12. Horiike S, Yokota S, Nakao M, Iwai T, Sasai Y, Kaneko H, Taniwaki M, Kashima K, Fujii H, Abe T, Misawa S. 1997. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia 11:1442-1446.
13. Ikezoe T, Nishioka C, Tasaka T, Yang Y, Komatsu N, Togitani K, Koeffler HP, Taguchi H. 2006. The antitumor effects of sunitinib (formerly SU11248) against a variety of human hematologic malignancies: Enhancement of growth inhibition via inhibition of mammalian target of rapamycin signaling. Mol Cancer Ther 5:2522-2530.
14. ISCN. 1995. An International System for Human Cytogenetic Nomenclature. Mitelman F (ed). Basel: S. Karger.
15. Iwai T, Yokota S, Nakao M, Okamoto T, Taniwaki M, Onodera N, Watanabe A, Kikuta A, Tanaka A, Asami K, Sekine I, Mugishima H, Nishimura Y, Koizumi S, Horikoshi Y, Mimaya J, Ohta S, Nishikawa K, Iwai A, Shimokawa T, Nakayama M, Kawakami K, Gushiken T, Hyakuna N, Katano N, Tsurusawa M, Fujimoto T. 1999. Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children's Cancer and Leukemia Study Group, Japan. Leukemia 13:38-43.
16. Johansson P, Hakkinen J. 2006. Improving missing value imputation of microarray data by using spot quality weights. BMC Bioinformatics 7:306.
17. Kang HJ, Hong SH, Kim IH, Park BK, Han KS, Cho HI, Shin HY, Ahn HS. 2005. Prognostic significance of FLT3 mutations in pediatric non-promyelocytic acute myeloid leukemia. Leuk Res 29:617-623.
18. Kiyoi H, Towatari M, Yokota S, Hamaguchi M, Ohno R, Saito H, Naoe T. 1998. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 12:1333-1337.
19. Kiyoi H, Ohno R, Ueda R, Saito H, Naoe T. 2002. Mechanism of constitutive activation of FLT3 with internal tandem duplication in the juxtamembrane domain. Oncogene 21:2555-2563.
20. Knapper S, Burnett AK, Littlewood T, Kell WJ, Agrawal S, Chopra R, Clark R, Levis MJ, Small D. 2006. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 108:3262-3270.
21. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, Walker H, Wheatley K, Bowen DT, Burnett AK, Goldstone AH, Linch DC. 2001. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: Analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 98:1752-1759.
22. Lacayo NJ, Meshinchi S, Kinnunen P, Yu R, Wang Y, Stuber CM, Douglas L, Wahab R, Becton DL, Weinstein H, Chang MN, Willman CL, Radich JP, Tibshirani R, Ravindranath Y, Sikic BI, Dahl GV. 2004. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLF3 mutations with good clinical outcomes. Blood 104:2646-2654.
23. Liang DC, Shih LY, Hung IJ, Yang CP, Chen SH, Jaing TH, Liu HC, Chang WH. 2002. Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia. Cancer 94:3292-3298.
24. Liang DC, Shih LY, Hung IJ, Yang CP, Chen SH, Jaing TH, Liu HC, Wang LY, Chang WH. 2003. FLT3-TKD mutation in childhood acute myeloid leukemia. Leukemia 17:883-886.
25. Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, Tjoa TK, Bernstein ID, Radich JP. 2001. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 97:89-94.
26. Meshinchi S, Alonzo TA, Stirewalt DL, Zwaan M, Zimmerman M, Reinhardt D, Kaspers GJ, Heerema NA, Gerbing R, Lange BJ, Radich JP. 2006. Clinical implications of FLT3 mutations in pediatric AML. Blood 108:3654-3661.
27. Mizuki M, Fenski R, Halfter H, Matsumura I, Schmidt R, Muller C, Gruning W, Kratz-Albers K, Serve S, Steur C, Buchner F, Kienast J, Kanakura Y, Berdel WE, Serve H. 2000. Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways. Blood 96:3907-3914.
28. Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, Sonoda Y, Fujimoto T, Misawa S. 1996. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia 10:1911-1918.
29. Nakao M, Janssen JW, Erz D, Seriu T, Bartram CR. 2000. Tandem duplication of the FLT3 gene in acute lymphoblastic leukemia: A marker for the monitoring of minimal residual disease. Leukemia 14:522-524.
30. Ozeki K, Kiyoi H, Hirose Y, Iwai M, Ninomiya M, Kodera Y, Miyawaki S, Kuriyama K, Shimazaki C, Akiyama H, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Ueda R, Ohno R, Emi N, Naoe T. 2004. Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 103:1901-1908.
31. Paietta E, Ferrando AA, Neuberg D, Bennett JM, Racevskis J, Lazarus H, Dewald G, Rowe JM, Wiernik PH, Tallman MS, Look AT. 2004. Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. Blood 104:558-560.
32. Parcells BW, Ikeda AK, Simms-Waldrip T, Moore TB, Sakamoto KM. 2006. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia. Stem Cells 24:1174-1184.
33. Paulsson K, Horvat A, Strömbeck B, Nilsson F, Heldrup J, Behrendtz M, Forestier E, Andersson A, Fioretos T, Johansson B. 2008. Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia. Genes Chromosomes and Cancer 47:26-33.
34. Ross ME, Zhou X, Song G, Shurtleff SA, Girtman K, Williams WK, Liu HC, Mahfouz R, Raimondi SC, Lenny N, Patel A, Downing JR. 2003. Classification of pediatric acute lymphoblastic leukemia by gene expression profiling. Blood 102:2951-2959.
35. Saal LH, Troein C, Vallon-Christersson J, Gruvberger S, Borg Å, Peterson C. 2002. BioArray Software Environment (BASE): A platform for comprehensive management and analysis of microarray data. Genome Biol 3:SOFTWARE0003.
36. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, Braisted J, Klapa M, Currier T, Thiagarajan M, Sturn A, Snuffin M, Rezantsev A, Popov D, Ryltsov A, Kostukovich E, Borisovsky 1, Liu Z, Vinsavich A, Trush V, Quackenbush J. 2003. TM4: A free, open-source system for microarray data management and analysis. Biotechniques 34:374-378.
37. Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, Löffler H, Sauerland CM, Serve H, Büchner F, Haferlach T, Hiddemann W. 2002. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: Correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 100:59-66.
38. Side LE, Curtiss NP, Teel K, Kratz C, Wang PW, Larson RA, Le Beau MM, Shannon KM. 2004. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. Genes Chromosomes Cancer 39:217-223.
39. Stam RW, den Boer ML, Schneider P, Nollau P, Horstmann M, Beverloo HB, van der Voort E, Valsecchi MG, de Lorenzo P, Sallan SE, Armstrong SA, Pieters R. 2005. Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia. Blood 106:2484-2490.
40. Stirewalt DL, Radich JP. 2003. The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 3:650-665.
41. Taketani T, Taki T, Sugita K, Furuichi Y, Ishii E, Hanada R, Tsuchida M, Ida K, Hayashi Y. 2004. FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy. Blood 103:1085-1088.
42. Thiede C, Steudel C, Mohr B, Schaich M, Schäkel U, Platzbecker U, Wermke M, Bornhäuser M, Ritter M, Neubauer A, Ehninger G, Illmer T. 2002. Analysis of FLT3-activaring mutations in 979 patients with acute myelogenous leukemia: Association with FAB subtypes and identification of subgroups with poor prognosis. Blood 99:4326-4335.
43. Tse KF, Mukherjee G, Small D. 2000. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia 14:1766-1776.
44. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, Barjesteh van Waalwijk van Doorn-Khosrovani S, Boer JM, Beverloo HB, Moorhouse MJ, van der Spek PJ, Löwenberg B, Delwel R. 2004. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 350:1617-1628.
45. Van Vlierberghe P, Meijerink JP, Stam RW, van der Smissen W, van Wering FR, Beverloo HB, Pieters R. 2005. Activating FLT3 mutations in CD4+/CD8- pediatric T-cell acute lymphoblastic leukemias. Blood 106:4414-4415.
46. Xu F, Taki T, Yang HW, Hanada R, Hongo T, Ohnishi H, Kobayashi M, Bessho F, Yanagisawa M, Hayashi Y. 1999. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Br J Haematol 105:155-162.
47. Yamamoto Y, Kiyoi H, Nakano Y, Suzuki R, Kodera Y, Miyawaki S, Asou N, Kuriyama K, Yagasaki F, Shimazaki C, Akiyama H, Saito K, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Saito H, Ueda R, Ohno R, Naoe T. 2001. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97:2434-2439.
48. Yamamoto T, Isomura M, Xu Y, Liang J, Yagasaki H, Kamachi Y, Kudo K, Kiyoi H, Naoe T, Kojma S. 2006. PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia. Leuk Res 30:1085-1089.
49. Yeoh EJ, Ross ME, Shurtleff SA, Williams WK, Patel D, Mahfouz R, Behm FG, Raimondi SC, Rolling MV, Patel A, Cheng C, Campana D, Wilkins D, Zhou X, Li J, Liu H, Pui CH, Evans WE, Naeve C, Wong L, Downing JR. 2002. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1:133-143.
50. Zwaan CM, Meshinchi S, Radich JP, Veerman AJ, Huismans DR, Munske L, Podleschny M, Hablen K, Pieters R, Zimmermann M, Reinhardt D, Harbott J, Creutzig U, Kaspers GJ, Griesinger F. 2003. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: Prognostic significance and relation to cellular drug resistance. Blood 102:2387-2394.